Novo Nordisk has filed two patent infringement suits in federal court seeking to block Mylan from developing a generic form of Ozempic.

The Ozempic manufacturer, represented in both cases by Fenwick & West, filed one complaint on Wednesday in the District of Delaware, then filed a nearly identical one in the Northern District of West Virginia.